Gland Pharma has announced a board meeting scheduled for November 3, 2025, to review and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025 (Q2). The company also announced the trading window, which closed on October 1, 2025, will reopen on November 6, 2025. An investor/analyst call will be held on November 3, 2025.
Board Meeting Announcement
Gland Pharma’s Board of Directors will meet on Monday, November 3, 2025, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025.
Trading Window Update
The trading window, which was previously closed starting Wednesday, October 1, 2025, will reopen on Thursday, November 6, 2025.
Investor/Analyst Call
An Investor/Analyst call is scheduled for Monday, November 3, 2025, at 18:30 Hrs (IST). Further details will be published on the company’s website.
Source: BSE
